Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K.

Neurobiol Aging. 2010 Mar;31(3):357-67. doi: 10.1016/j.neurobiolaging.2008.03.027. Epub 2008 May 19.

PMID:
18486992
2.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
3.

Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.

Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.

Neurodegener Dis. 2008;5(5):268-76. doi: 10.1159/000119457. Epub 2008 Feb 29.

PMID:
18309230
4.

Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.

Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE, Scheltens P, Blankenstein MA, Veerhuis R.

Dement Geriatr Cogn Disord. 2008;26(6):522-7. doi: 10.1159/000178756. Epub 2008 Dec 2. Erratum in: Dement Geriatr Cogn Disord. 2009;27(6):584.

PMID:
19052452
5.

No correlation between time-linked plasma and CSF Abeta levels.

Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

Neurochem Int. 2009 Dec;55(8):820-5. doi: 10.1016/j.neuint.2009.08.006. Epub 2009 Aug 18.

PMID:
19695299
6.

Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.

Neurobiol Aging. 2009 Feb;30(2):165-73. Epub 2007 Jul 23.

PMID:
17646035
7.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19.

PMID:
17374949
8.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
9.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.

Neurobiol Aging. 2006 Feb;27(2):237-44. Epub 2005 Apr 7.

PMID:
16399209
10.

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.

Neurology. 2007 Aug 14;69(7):631-9.

PMID:
17698783
11.

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P.

Neurobiol Aging. 2008 Jan;29(1):1-11. Epub 2006 Oct 19.

PMID:
17055615
12.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
13.

Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA.

Neurobiol Aging. 2010 Apr;31(4):539-40; author reply 541. doi: 10.1016/j.neurobiolaging.2008.07.024. Epub 2008 Oct 28. No abstract available.

PMID:
18963255
14.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
15.

Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).

Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P.

Curr Alzheimer Res. 2005 Dec;2(5):527-39.

PMID:
16375656
16.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
17.

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.

Mech Ageing Dev. 2006 Feb;127(2):129-32. Epub 2005 Nov 7.

PMID:
16274728
18.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
19.

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K.

Neurosci Lett. 1999 Sep 24;273(1):5-8.

PMID:
10505638
20.

Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.

Jung SM, Lee K, Lee JW, Namkoong H, Kim HK, Kim S, Na HR, Ha SA, Kim JR, Ko J, Kim JW.

Neurosci Lett. 2008 May 9;436(2):153-7. doi: 10.1016/j.neulet.2008.03.010. Epub 2008 Mar 18.

PMID:
18378077

Supplemental Content

Support Center